Citigroup’s NEVRO CORP. NVRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-26,134
| Closed | -$153K | – | 5987 |
|
|
2025
Q1 | $153K | Sell |
26,134
-2,281
| -8% | -$12K | ﹤0.01% | 4344 |
|
|
2024
Q4 | $106K | Buy |
28,415
+471
| +2% | +$2.17K | ﹤0.01% | 4809 |
|
|
2024
Q3 | $156K | Buy |
27,944
+16,479
| +144% | +$115K | ﹤0.01% | 4523 |
|
|
2024
Q2 | $96.5K | Sell |
11,465
-6,835
| -37% | -$72.9K | ﹤0.01% | 4231 |
|
|
2024
Q1 | $264K | Buy |
18,300
+13,241
| +262% | +$219K | ﹤0.01% | 3894 |
|
|
2023
Q4 | $109K | Buy |
5,059
+3,721
| +278% | +$66.4K | ﹤0.01% | 4169 |
|
|
2023
Q3 | $25.7K | Sell |
1,338
-11,331
| -89% | -$242K | ﹤0.01% | 4327 |
|
|
2023
Q2 | $322K | Buy |
12,669
+10,576
| +505% | +$305K | ﹤0.01% | 3645 |
|
|
2023
Q1 | $75.7K | Sell |
2,093
-12,023
| -85% | -$422K | ﹤0.01% | 4128 |
|
|
2022
Q4 | $559K | Buy |
14,116
+11,302
| +402% | +$470K | ﹤0.01% | 3083 |
|
|
2022
Q3 | $132K | Sell |
2,814
-2,058
| -42% | -$95.5K | ﹤0.01% | 3968 |
|
|
2022
Q2 | $214K | Buy |
4,872
+2,529
| +108% | +$139K | ﹤0.01% | 3816 |
|
|
2022
Q1 | $170K | Sell |
2,343
-7,315
| -76% | -$527K | ﹤0.01% | 4163 |
|
|
2021
Q4 | $783K | Buy |
9,658
+5,108
| +112% | +$512K | ﹤0.01% | 3479 |
|
|
2021
Q3 | $530K | Buy |
4,550
+1,129
| +33% | +$148K | ﹤0.01% | 3564 |
|
|
2021
Q2 | $567K | Sell |
3,421
-6,036
| -64% | -$942K | ﹤0.01% | 3617 |
|
|
2021
Q1 | $1.32M | Sell |
9,457
-16,081
| -63% | -$2.62M | ﹤0.01% | 2774 |
|
|
2020
Q4 | $4.42M | Buy |
25,538
+7,806
| +44% | +$1.26M | ﹤0.01% | 2178 |
|
|
2020
Q3 | $2.47M | Sell |
17,732
-1,663
| -9% | -$222K | ﹤0.01% | 2467 |
|
|
2020
Q2 | $2.32M | Buy |
19,395
+2,974
| +18% | +$353K | ﹤0.01% | 2651 |
|
|
2020
Q1 | $1.64M | Buy |
16,421
+8,850
| +117% | +$1.06M | ﹤0.01% | 2679 |
|
|
2019
Q4 | $890K | Buy |
7,571
+1,349
| +22% | +$134K | ﹤0.01% | 3876 |
|
|
2019
Q3 | $535K | Sell |
6,222
-3,437
| -36% | -$260K | ﹤0.01% | 4275 |
|
|
2019
Q2 | $626K | Buy |
9,659
+250
| +3% | +$15.6K | ﹤0.01% | 4194 |
|
|
2019
Q1 | $588K | Buy |
9,409
+3,512
| +60% | +$165K | ﹤0.01% | 4009 |
|
|
2018
Q4 | $229K | Sell |
5,897
-1,715
| -23% | -$76.2K | ﹤0.01% | 4881 |
|
|
2018
Q3 | $434K | Buy |
7,612
+6,285
| +474% | +$393K | ﹤0.01% | 4454 |
|
|
2018
Q2 | $106K | Buy |
1,327
+771
| +139% | +$64K | ﹤0.01% | 5668 |
|
|
2018
Q1 | $48K | Sell |
556
-42
| -7% | -$3.39K | ﹤0.01% | 6204 |
|
|
2017
Q4 | $41K | Sell |
598
-1,921
| -76% | -$154K | ﹤0.01% | 6316 |
|
|
2017
Q3 | $229K | Buy |
2,519
+2,073
| +465% | +$177K | ﹤0.01% | 4879 |
|
|
2017
Q2 | $33K | Buy |
446
+109
| +32% | +$8.73K | ﹤0.01% | 6042 |
|
|
2017
Q1 | $32K | Sell |
337
-3,294
| -91% | -$298K | ﹤0.01% | 6000 |
|
|
2016
Q4 | $264K | Buy |
3,631
+1,672
| +85% | +$143K | ﹤0.01% | 5051 |
|
|
2016
Q3 | $205K | Sell |
1,959
-2,147
| -52% | -$194K | ﹤0.01% | 4626 |
|
|
2016
Q2 | $304K | Sell |
4,106
-8,903
| -68% | -$604K | ﹤0.01% | 4124 |
|
|
2016
Q1 | $731K | Buy |
13,009
+12,781
| +5,606% | +$754K | ﹤0.01% | 3709 |
|
|
2015
Q4 | $15K | Sell |
228
-7,275
| -97% | -$390K | ﹤0.01% | 6632 |
|
|
2015
Q3 | $348K | Buy |
7,503
+7,306
| +3,709% | +$354K | ﹤0.01% | 4071 |
|
|
2015
Q2 | $11K | Sell |
197
-273
| -58% | -$13.9K | ﹤0.01% | 6426 |
|
|
2015
Q1 | $22K | Sell |
470
-910
| -66% | -$39.5K | ﹤0.01% | 6059 |
|
|
2014
Q4 | $53K | Buy |
+1,380
| New | +$43.5K | ﹤0.01% | 5655 |
|
Other funds holding NVRO
Citigroup's NVRO Position: Q2 2025 in Review
Citigroup sold out of NEVRO CORP. (NVRO) in Q2 2025, closing a stake of 26,134 shares — an estimated $153K sold.
Citigroup first reported a position in NVRO in Q4 2014 and held it in 42 quarters. The position peaked at $4.42M in Q4 2020. 1 fund tracked by Wall St. Rank holds NVRO as of Q2 2025.
- Citigroup reported no remaining NEVRO CORP. position as of Q2 2025 after selling out during the quarter.
- Citigroup sold 26,134 NEVRO CORP. shares in Q2 2025, an estimated $153K.
- Citigroup first reported a position in NEVRO CORP. in Q4 2014 and held it in 42 quarters.
- Citigroup's NEVRO CORP. position peaked at $4.42M in Q4 2020.
- 1 fund tracked by Wall St. Rank held NEVRO CORP. as of Q2 2025.
Based on Citigroup's 13F filing for Q2 2025, filed 11 Aug 2025.